Dechra Veterinary Products has announced that it will be launching Zycortal, a new medication for the treatment of canine hypoadrenocorticism at the BSAVA Congress in April.
Zycortal is a prolonged-release suspension used as replacement therapy for mineralocorticoid deficiency in dogs with Addison’s disease. Dechra says it has proved highly effective in clinical trials with more than 80% of dogs responding positively to treatment1.
Zycortal contains desoxycortone pivalate (DOCP) which Dechra says controls serum electrolytes more effectively than fludrocortisone2 (the human treatment currently prescribed for dogs with Addison’s disease) and is considered the preferential drug for mineralocorticoid supplementation.
Zycortal is the only European licensed treatment for canine hypoadrenocorticism and adds to Dechra’s existing endocrinology range.
Visitors to the BSAVA Congress will be able to find out more about Zycortal at the Dechra stand (500). Delegates are also invited to attend a presentation by Professor Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS on Saturday, April 9, at 11.10am.
The presentation, New developments in the diagnosis and management of Addison’s disease aims to give delegates an insight into the condition.
Dechra Brand Manager Craig Sankey said: "We are very excited to be able to bring Zycortal to veterinary professionals in the UK. Addison’s disease can be very hard to diagnose as it mimics so many other illnesses.
"Each injection of Zycortal lasts approximately one month, providing long-term control of primary Addison’s disease. The prognosis for dogs with Addison’s disease is excellent provided that treatment is maintained for life. Our team will be on hand at the BSAVA Congress to explain and discuss the benefits that Zycortal can bring to their day to day practice in the fight against this illness."
References
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.